Exchange: NASDAQ·Updated 07:30 PM EST
IMUX logo

IMUX Immunic Inc

$7.23
$0.29
(3.86%)
Today
Closed $7.23
$0.00
(0.00%)
After Hours
Reported EarningsNov 13
Mkt Cap$102.61M
Vol171,158.00

About IMUX

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on multiple sclerosis, celiac disease and other neurologic and gastrointestinal disorders. The firm's products include IMU-838, IMU-856, and IMU-381. The company was founded in 2016 and is headquartered in New York, NY.
44

Bearish Sentiment

How do you feel about IMUX?

Mvvh1987
$IMUX Stifel reinforced why I’m so bullish on the leadership. Lundgren helped build and launch Ocrevus and knows what it takes to create a blockbuster in a “crowded” MS market. Tardio knows how to position and commercialize MS therapies. Their message was clear: ~30% relapse reduction + strong MRI + differentiated safety/tolerability could make VidoCa highly competitive. December decides.
10
MrInvestor67
$IMUX They announced enrollment completed on June 5, 2025. When they issue press release like this means last patient first dose already happened before June 5th last year. It’s a 72 week dosing study. As of today 75 weeks elapsed since the last patient enrollment completed. So last patient last dose happened 3 weeks ago. Typically it takes 2 to 6 weeks for topline results. The worst case is 3 weeks from now. The base case is end of November. Best case is any day from today. My hunch is the management already has topline results in their hands. Let’s hope that they are sitting on great results for the sake of patients.
12
BioGem
$IMUX I took a small position. The stock is like a call option. Probabilistically, there is more than 50% chance of success, and if so, this will re-rate to the billion-dollar market cap, which means several folds higher on the stock price. -Phase 2 trial data is solid. -Multiple top biotech hedge funds entered the stock earlier this year, knowing that they have several PhD who have done deep dive due diligence of the underlying science. $XBI $IBB
9
MrInvestor67
$IMUX The management reiterated timeline for topline in December means, they have all the data they need to crunch. The database unlock must have happened already or about to be unlocked this month. I wouldn’t be surprised to see topline results in first week of December.
9
GrowerWJR
$IMUX fully diluted share count including the warrants are around 70m. So the current market cap is around 500m, not 100m. Last week they said they’re expecting a 30% reduction compared to placebo, but I think for commercial success without a doubt, it should be around at least 35-40%. Teriflunomide kind of exceeds their initial phase 3 results in the latest superiority trials with other drugs as well. Clean safety+35-40% reduction should give IMUX enough edge to be competitive in the market.
6
MrInvestor67
$IMUX I believe shorts will now start covering after dismal NVS results. We will see gradual increase in share price until ENSURE results are announced
7
Butterss
$IMUX ive held for this position for about a year with just under 11k shares at avg price 10.4
5
Mvvh1987
$IMUX Toronto looked like a win. 4 posters, strong engagement around the paper posters and a busy booth. More importantly, the story keeps expanding beyond RMS into disability progression, Nurr1/neuroprotection and progressive MS. ENSURE remains the key catalyst, but the potential franchise value keeps getting more interesting.
5
Mattjen
$IMUX Another encouraging update from $IMUX. The new CALLIPER data support sustained disability benefits, while the Nurr1 and EBV findings continue to strengthen the science behind vidofludimus calcium. The disability improvement signals are particularly interesting. Still need Phase 3 confirmation, but the overall picture continues to look promising. All eyes on ENSURE topline!
5
BiotechSwings
December is the whole story on $IMUX imo twin Phase 3 ENSURE trials, vidofludimus calcium in relapsing multiple sclerosis, topline expected next month 2,221 patients randomized across both studies. that is not a small swing closed 7.79 yesterday, softer again this morning, and the readout has not moved
4
Jw242
$IMUX volume really needs a sip of something…..anemic is being kind Coulda been a great day to 🏃
4
Mvvh1987
$IMUX Yesterday’s Progressive MS R&D Day strengthened the long-term story for me. PROTECT-MS is becoming a real Phase 3 strategy targeting disability progression across PPMS and non-active SPMS, not just another exploratory program. ENSURE remains the near-term key, but if RMS delivers, the progressive MS upside could turn vidofludimus into a much broader MS franchise.
4
Mattjen
$IMUX going to be a crazy month! I hope us longs and recent investors are rewarded handsomely. God bless you
4
Merlintrader
Latest company news, October 19, 2026: Immunic appointed Jaa Roberson as Chief People Officer, a newly created role, ahead of the pivotal Phase 3 ENSURE read-out expected by the end of 2026. Immunic $IMUX Stock Hub Not investment advice. More details in our stock hub.
4
Mattjen
$IMUX new 13 G... 32.27% increase (over severa momths) in Aberdeen's position heading into topline! Correct me if I'm wrong.
3
Jw242
$IMUX nightmare markets to try a bit of a rebound before data eh? Not easy to fight this
1
Butterss
$IMUX this tests my ability to not cut my losses. Im just gonna set a price alert see yall in december
2
Merlintrader
$IMUX Latest company news, Oct 21, 2026: Immunic presented four posters at MSToronto 2026. Open-label extension data from the Phase 2 CALLIPER trial of vidofludimus calcium supported the durability of disability outcomes seen in the double-blind period, with a consistent safety profile. These are exploratory analyses. More news in our $IMUX stock hub on Merlintrader. Not investment advice.
1
Jack8alot
$IMUX Chief People Officer Wouldve been a good job for me. 400k a year stock options. Im in
1
fernfernfern
$IMUX Are we expecting the date of the data release to be announced at Guggenheim on the 9th?

Advertisement|Remove ads.